133 related articles for article (PubMed ID: 1378111)
1. Mechanism of antiarrhythmic efficacy of propafenone as assessed by programmed electrical stimulation in conscious dogs.
Todt H; Krumpl G; Krejcy K; Raberger G
J Cardiovasc Pharmacol; 1992 Mar; 19(3):341-8. PubMed ID: 1378111
[TBL] [Abstract][Full Text] [Related]
2. Lidocaine has a narrow antiarrhythmic dose range against ventricular arrhythmias induced by programmed electrical stimulation in conscious postinfarction dogs.
Krejcy K; Krumpl G; Todt H; Raberger G
Naunyn Schmiedebergs Arch Pharmacol; 1992 Aug; 346(2):213-8. PubMed ID: 1448183
[TBL] [Abstract][Full Text] [Related]
3. Effect of ajmaline on sustained ventricular tachycardia induced by programmed electrical stimulation in conscious dogs after myocardial infarction.
Todt H; Krumpl G; Zojer N; Krejcy K; Raberger G
Naunyn Schmiedebergs Arch Pharmacol; 1993 Sep; 348(3):290-7. PubMed ID: 7694159
[TBL] [Abstract][Full Text] [Related]
4. Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.
Winslow E; Campbell JK; Barron E; Marshall RJ; Muir AW
Br J Pharmacol; 1991 Dec; 104(4):853-8. PubMed ID: 1810599
[TBL] [Abstract][Full Text] [Related]
5. Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation.
Doherty JU; Waxman HL; Kienzle MG; Cassidy DM; Marchlinski FE; Buxton AE; Josephson ME
J Am Coll Cardiol; 1984 Aug; 4(2):378-81. PubMed ID: 6736479
[TBL] [Abstract][Full Text] [Related]
6. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects.
Kirchhof PF; Fabritz CL; Franz MR
Circulation; 1998 Jun; 97(25):2567-74. PubMed ID: 9657478
[TBL] [Abstract][Full Text] [Related]
7. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
Black SC; Butterfield JL; Lucchesi BR
J Cardiovasc Pharmacol; 1993 Dec; 22(6):810-8. PubMed ID: 7509898
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart.
Fazekas T; Carlsson L; Scherlag BJ; Mabo P; Poty H; Palmer M; Patterson E; Berlin KD; Garrison GL; Lazzara R
J Cardiovasc Pharmacol; 1996 Aug; 28(2):182-91. PubMed ID: 8856472
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of cibenzoline and propafenone against inducible sustained and nonsustained ventricular tachycardias in conscious dogs with isolated chronic right ventricular infarction: a comparative study with procainamide.
Karagueuzian HS; Sugi K; Ohta M; Meesmann M; Ino T; Peter T; Mandel WJ
Am Heart J; 1986 Dec; 112(6):1173-83. PubMed ID: 3788764
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia.
Shen EN; Sung RJ; Morady F; Schwartz AB; Scheinman MM; DiCarlo L; Shapiro W
J Am Coll Cardiol; 1984 May; 3(5):1291-7. PubMed ID: 6707382
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the antiarrhythmic profile of the new class I agent diprafenone.
Gülker H; Thale J; Olbing B; Heuer H; Frenking B; Bender F
Arzneimittelforschung; 1985; 35(9):1387-93. PubMed ID: 4084340
[TBL] [Abstract][Full Text] [Related]
12. Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: a comparative study with dobutamine.
Ozaki T; Uematsu T; Nagashima S; Nishimoto M; Nakashima M
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):478-87. PubMed ID: 1766473
[TBL] [Abstract][Full Text] [Related]
13. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
Drexler AP; Micklas JM; Brooks RR
J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiologic effects of oral propafenone in Wolff-Parkinson-White syndrome studied by programmed electrical stimulation.
Sethi KK; Prasad GS; Mohan JC; Arora R; Khalilullah M
Indian Heart J; 1991; 43(1):5-10. PubMed ID: 1894303
[TBL] [Abstract][Full Text] [Related]
15. The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent.
Black SC; Chi LG; Mu DX; Lucchesi BR
J Pharmacol Exp Ther; 1991 Aug; 258(2):416-23. PubMed ID: 1865349
[TBL] [Abstract][Full Text] [Related]
16. Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion.
Aidonidis I; Brachmann J; Rizos I; Zacharoulis A; Stavridis I; Toutouzas P; Kübler W
Cardiovasc Drugs Ther; 1995 Aug; 9(4):555-63. PubMed ID: 8547205
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia.
Chilson DA; Heger JJ; Zipes DP; Browne KF; Prystowsky EN
J Am Coll Cardiol; 1985 Jun; 5(6):1407-13. PubMed ID: 3889099
[TBL] [Abstract][Full Text] [Related]
18. Antidysrhythmic actions of meobentine sulfate.
Zimmerman JM; Patterson E; Pitt B; Lucchesi B
Am Heart J; 1984 Jun; 107(6):1117-24. PubMed ID: 6720538
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of propafenone in preventing ventricular tachycardia: inverse correlation with rate-related prolongation of conduction time.
Kus T; Dubuc M; Lambert C; Shenasa M
J Am Coll Cardiol; 1990 Nov; 16(5):1229-37. PubMed ID: 2229772
[TBL] [Abstract][Full Text] [Related]
20. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.
Wang J; Bourne GW; Wang Z; Villemaire C; Talajic M; Nattel S
Circulation; 1993 Sep; 88(3):1030-44. PubMed ID: 8353865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
